Posts by MSI
There are 8 results found
Interrogating Ligand: Target Interactions Using Back-Scattering Interferometry Yields Mechanistic Insight and Aids in Compound Prioritization
Interrogating Ligand: Target Interactions Using Back-Scattering Interferometry Yields Mechanistic Insight and Aids in Compound Prioritization
Dr. Layton Harris Smith, Director, Drug Discovery – Florida, Sanford Burnham Prebys Medical Discovery Institute
Presented on January 26, 2016 at a SLAS2016
Dr. Smith is the Director of Drug Discovery and Pharmacology at the Sanford Burnham Prebys Medical Discovery Institute in Orlando, Florida. In this role he provides overall operational and scientific leadership to the Conrad Prebys Center for Chemical Genomics at the Institute, a 30-person drug discovery enterprise equipped with state of the art ultra-high throughput screening and lead discovery capabilities. He directs the efforts of cross functional, multidisciplinary teams to advance a pipeline of therapeutic molecules from concept to pre-clinical in vivo efficacy studies with the goal of discovering first-in-class breakthrough drugs to meet today’s most urgent unmet medical needs.
Among his varied responsibilities, Layton is also the Principal Investigator of the Florida Translational Research Program. This innovative, collaborative drug discovery initiative affords researchers at Florida-based universities access to the talent and technology platforms of the drug discovery group at Sanford Burnham Prebys. This program has executed over 30 collaborative drug discovery projects with 15 different institutions and generated several patents. Discoveries resulting from this effort are currently being partnered with pharmaceutical and biotech companies.
Layton earned his Doctor of Philosophy in Pharmacology at Vanderbilt University. In 2005, he returned to his home state of Florida to join The Scripps Research Institute where he played a key role in the establishment of the institute’s Florida operations. In 2007, he was recruited to Sanford Burnham Prebys. Dr. Smith is the author of more than 50 peer-reviewed manuscripts and an inventor on three patents.
PLEASE FILL OUT THIS SHORT REGISTRATION FORM TO VIEW THE PRESENTATION NOW
Review of Recent Publications Featuring Binding Data Produced by MSI
Review of Recent Publications Featuring Binding Data Produced by Molecular Sensing’s Drug Discovery Services
Presented by Dr. Jake Isaacs, Applied Research Sciences Manager at Molecular Sensing, Inc.
Richard “Jake” Isaacs, PhD, oversees the applied research laboratories of Molecular Sensing, Inc., providing access to the proprietary back-scattering interferometry (BSI) technology platform to pharmaceutical and biotechnology companies.
Through ongoing drug discovery service projects, his group is able to characterize small molecule binding to drug targets that have traditionally been difficult to assay by established technologies.
Dr. Isaacs received his doctorate in biochemistry from the University of Kentucky in 2003 and received postdoctoral training in immunology, microbiology, and molecular diagnostics at Vanderbilt University.
PLEASE FILL OUT THIS SHORT REGISTRATION FORM TO VIEW THE PRESENTATION NOW
MSI Featured in GEN Article on Precision Tuning GPCR Pathways
Precision Tuning GPCR Pathways The Cell, Like an Engine, May Need a Tune-Up for Optimal Performance, or Even a Smooth Idle Written by Lisa Heiden for the issue released on Apr 15, 2015 (Vol. 35, No. 8) MSI is […]
SLAS2015 Tutorial Player – Weinberger
Use your cursor to rollover the screen to see the video controls.
Conformation-Sensitive Assay Detection for Accelerated Drug Discovery Research
Conformation-Sensitive Assay Detection for Accelerated Drug Discovery Research
Learn about the superior analytical power of TruBind™ Back Scattering Interferometry (BSI) technology for molecular interaction studies.
TruBind BSI technology offers significant advantages over conventional methods by providing direct binding Kd determinations and confirming target engagement by leveraging label-free, conformation-sensitive detection. Designed to analyze complex and intractable drug targets maintained in native or native-like environments, this technology platform is ideal for studying allosteric kinases and GPCR’s as membrane preps, solubilized proteins, nanodiscs or amphipols, Ion Channels, RTK’s, Allosteric Contractile Proteins, Tau and Alpha Synuclein Fibrils, Transcription Factors, and Transporter Proteins.
Molecular Sensing’s tutorial begins with a brief review of the science and technology fundamentals and then proceeds to a detailed discussion of the direct application of TruBind BSI technology to a variety of challenging targets. Come learn about TruBind Assay Services and the TruBind 100 System to see how BSI technology can accelerate your drug discovery research.
Presented by Scot Weinberger
Director, Co-Founder, Executive Vice President, Molecular Sensing Inc.
Scot has over 20 years of experience in life science instrumentation development before founding Molecular Sensing. Most recently, he founded GenNext Technologies, a company dedicated to advancing education in translational medicine. Scot was Director of Research Proteomics for Ciphergen Biosystems, where he led R&D in mass spectrometry and molecular interaction technology. Earlier in his career he was VP of R&D at Linear Scientific, which he helped sell to Hewlett-Packard and Spectra-Physics and subsequently held key R&D positions at both companies. Scot’s academic training was in cellular biology with a BS degree and post-graduate medical school training from the University of Nevada, Reno. Scot holds 30 different US and international patents in the areas of life science research.
Originally presented as Exhibitor Tutorial at SLAS2015 in February 2015 Washington, DC.
FILL OUT THIS SHORT REGISTRATION FORM TO VIEW THE PRESENTATION NOW
Evaluation of the MoA of Allosteric Modulators and Its Application to Drug Discovery using Back-Scattering Interferometry
Evaluation of the MoA of Allosteric Modulators and Its Application to Drug Discovery using Back-Scattering Interferometry
Dr. Jeff Reagan, Scientific Director, Department of Metabolic Disorders, Amgen, Inc.
Scot Weinberger, Director, Co-Founder, Executive Vice President of Molecular Sensing Inc.
Presented on November 13, 2015 at a CHI Web Symposia
Symposium Overview
This symposium describes the unique strengths of Back-Scattering Interferometry (BSI) for understanding the mechanism of action of allosteric drug targets in metabolic disease. The course commences with a brief review of BSI technology and principles and proceeds by reviewing a specific case study for a metabolic disease target. The strengths, advantages, and convenience of the BSI technique are emphasized and contrasted with radio-ligand assays. Other target examples are also presented including GPCR membrane preparations.
Learning Objectives
Speaker Bios
Scot Weinberger
Director, Co-Founder, Executive Vice President, Molecular Sensing Inc.
Director, Co-Founder, Executive Vice President, Molecular Sensing Inc.
Scot has over 20 years of experience in life science instrumentation development before founding Molecular Sensing. Most recently, he founded GenNext Technologies, a company dedicated to advancing education in translational medicine. Scot was Director of Research Proteomics for Ciphergen Biosystems, where he led R&D in mass spectrometry and molecular interaction technology. Earlier in his career he was VP of R&D at Linear Scientific, which he helped sell to Hewlett-Packard and Spectra-Physics and subsequently held key R&D positions at both companies. Scot’s academic training was in cellular biology with a BS degree and post-graduate medical school training from the University of Nevada, Reno. Scot holds 30 different US and international patents in the areas of life science research.
Jeff Reagan
Scientific Director, Department of Metabolic Disorders, Amgen, Inc.
Scientific Director, Department of Metabolic Disorders, Amgen, Inc.
Jeff Reagan received his PhD in chemistry from Yale University in 1986. He pursued postdoctoral studies at the Yale University School of Medicine in the Department of Neurobiology studying the molecular pharmacology of olfaction. He joined Sandoz/Novartis in 1989 working in the area of G protein coupled receptors. In 1998 he joined Affmax where he extended his work on the molecular pharmacology of GPCRs. In 2001 he joined Tularik (acquired by Amgen in 2004) and has worked in the area of diabetes, nephrology and cardiovascular disease with a specific emphasis in systolic heart failure. His key area of interest is the molecular pharmacology and mathematical modeling of allosteric modulators.
FILL OUT THIS SHORT REGISTRATION FORM TO VIEW THE PRESENTATION NOW
Using BSI to Investigate Positive Allosteric Modulators of the M4 Receptor
The use of Backscattering Interferometry to Investigate Positive Allosteric Modulators of the M4 Receptor
Presented by Dr. Jonathan Ellery, Principal Scientist, Takeda Cambridge, Ltd.
Presented on 3-September-2014, at the ELRIG Drug Discovery 2014 conference in Manchester, UK.
Presentation Overview
Evidence suggests that the activation of the muscarinic acetycholine receptors (mAChRs) in the central nervous system (CNS) may have therapeutic benefit in the treatment of a number of CNS disorders. The use of non-selective agonists is limited due to un-desirable peripheral side effects. One approach to overcome this issue is to identify compounds that selectively positively modulate the M4 mAChR subtype via an allosteric binding site. Here we describe the use of backscattering interferometry, a label free assay technology, to investigating the nature of modulator binding and its co-operative effects upon the binding of the natural ligand acetylcholine to the M4 mAChR.
About the Presenter
Dr. Jonathan Ellery is a principal scientist with 14 years of industrial experience working in the field of in vitro pharmacology. He has a keen interest in understanding how compounds engage with targets and seeks new methodologies and technologies that will further help in our understanding of this fundamental aspect of drug discovery.